Cell line · CVCL_1759
Papers48
1 to 20 of 48
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Inhibition of the AT-Hook DNA-Binding Domain Attenuates HMGA2-Mediated Epithelial Mesenchyme Transition in Esophageal Cancer Cells. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Elevated CHAF1A Suppresses Type I Interferon Production and Causes Immunotherapy Resistance in Esophageal Squamous Cell Carcinoma. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multiomic characterization of response and resistance to neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. | Transl Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The AGPS regulatory variant rs113671272 confers esophageal squamous cell carcinoma susceptibility through allele-specific MEIS3 binding and NF-κB activation in Chinese populations. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lactylome Reprogramming Mediates Therapeutic Response and Adaptation to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma. | Mol Cell Proteomics | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Noncanonical RNA-Binding Function of NQO1 Drives Angiogenesis in Esophageal Squamous Cell Carcinoma via Extracellular Vesicle-Mediated AGRN Transfer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| NIPAL1 Drives a Metabolic-Epigenetic Feedback Loop to Promote Lactate-Mediated Immune Evasion in Esophageal Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Spatio-Temporal Proteomic Landscape Reveals Early Warning Signals of Esophageal Squamous Cell Carcinoma Progression. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Characterization of tertiary lymphoid structure identifies competitive binding of CD40 and STING with TRAF2 driving IRF4-mediated B cell activation in esophageal squamous cell carcinoma. | Cancer Gene Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| NUDT21 lactylation reprograms alternative polyadenylation to promote cuproptosis resistance. | Cell Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Mechanism of Modified Tongyou Decoction and Its Separated Formulas Inhibiting Vasculogenic Mimicry in Esophageal Cancer TE-1 Cells via NF-κB/HIF-1α Axis. | Integr Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| MTHFD2 promotes esophageal squamous cell carcinoma progression via m6A modification‑mediated upregulation and modulation of the PEBP1‑RAF1 interaction. | Int J Mol Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Gram-Negative Microflora Dysbiosis Facilitates Tumor Progression and Immune Evasion by Activating the CCL3/CCL5-CCR1-MAPK-PD-L1 Pathway in Esophageal Squamous Cell Carcinoma. | Mol Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Re-evaluation of the relationship between PrPc expression and patient prognosis in primary esophageal squamous cell carcinoma and primary hepatocellular carcinoma. | Sci Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Plasma CircCYP24A1 as a Novel Biomarker of Esophageal Squamous Cell Carcinoma. | Technol Cancer Res Treat | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route. | Cancer Cell Int | 2024 | Its Methods give the RRID and name the line | PubMed | |
| SP4 Facilitates Esophageal Squamous Cell Carcinoma Progression by Activating PHF14 Transcription and Wnt/Β-Catenin Signaling. | Mol Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting LncRNA LLNLR-299G3.1 with antisense oligonucleotide inhibits malignancy of esophageal squamous cell carcinoma cells in vitro and in vivo. | Oncol Res | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1759/papers